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TargetingGadolinium-labelled nanocomplexes offer prospects for the development of real-time, non-invasive imaging
strategies to visualise the location of gene delivery by MRI. In this study, targeted nanoparticle formulations
were prepared comprising a cationic liposome (L) containing a Gd-chelated lipid at 10, 15 and 20% by weight
of total lipid, a receptor-targeted, DNA-binding peptide (P) and plasmid DNA (D), which electrostatically
self-assembled into LPD nanocomplexes. The LPD formulation containing the liposome with 15% Gd-chelated
lipid displayed optimal peptide-targeted, transfection efﬁciency. MRI conspicuity peaked at 4 h after incubation
of the nanocomplexes with cells, suggesting enhancement by cellular uptake and trafﬁcking. Thiswas supported
by time course confocal microscopy analysis of transfections with ﬂuorescently-labelled LPD nanocomplexes.
Gd-LPD nanocomplexes delivered to rat brains by convection-enhanced delivery were visible by MRI at 6 h,
24 h and 48 h after administration. Histological brain sections analysed by laser ablation-inductively coupled
plasma-mass spectrometry (LA-ICP-MS) conﬁrmed that the MRI signal was associated with the distribution of
Gd3+moieties and differentiatedMRI signals due to haemorrhage. The transfected brain cells near the injection
site appeared to bemostlymicroglial. This study shows the potential of Gd-LPD nanocomplexes for simultaneous
delivery of contrast agents and genes for real-time monitoring of gene therapy in the brain.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Nucleic acid therapeutics offer opportunities for the development of
new medicines for a diverse range of unmet clinical needs in the brain
including neurodegenerative diseases, neuromuscular diseases, and gli-
omas. Synthetic nanoparticle formulations, such as lipoplexes and
polyplexes, with a variety of chemical formulations are being investi-
gated for the delivery of therapeutic genes and siRNAs to the brain
[1,2]. Although systemic routes of delivery to the brain are an attractive
option for some formulations [3] for others delivery is often inefﬁcient
since the blood–brain barrier is highly selective and may exclude high
molecular weight nanoparticles [4]. Methods of direct administration
of nanoparticles to the brain, such as convection-enhanced delivery
(CED), physically bypass the BBB and can achieve widespread dispersal
of therapeutics from a single infusion with appropriate types of
nanoparticles [5–7].Unit, UCL Institute of Child
. Tel.: +44 20 7905 2228;
rights reserved.Not only is delivery to the brain problematic but also the inaccessi-
bility of the brain for sampling and monitoring of treatment presents
further challenges. Magnetic resonance imaging (MRI) provides a high
resolution non-invasive tool tomonitor brain pathologies and potential
treatment regimes using agents that affect image contrast. T1 agents
such as Gd are particularly useful as they produce a ‘bright’ spot on
MRl whereas T2 iron-containing contrast agents produce dark areas
and can suffer from problems of discriminating adjacent areas with
the same hypointensities. Generally, contrast agents for MRI offer limit-
ed sensitivity and so packaging of the Gd3+ contrast agents into
nanoparticles, such as liposomes or polymer based nanoparticles has
been investigated as a means to concentrate the agents and enhance
their speciﬁc delivery to the tissues of interest [8,9]. Thus, the properties
of different nanoparticle formulations, such as tissue targeting and cel-
lular uptake can be exploited to further enhance the diversity of possi-
ble biomedical applications of MRI [10].
We have described previously a formulation of liposomes and
receptor-targeted, cationic peptides, which self-assemble on mixing
with DNA or siRNA into nanocomplexes and display efﬁcient, targeted
transfection [11]. In this study we have investigated the potential of
these multifunctional nanocomplexes for imaging of distribution by
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Gd3+-chelated lipids formulated into the liposome component at a
range of concentrations (10–20% Gd3+) and assessed in transfections
of cultured cells to determine their MRI characteristics, transfection ef-
ﬁciency and toxicity. Then optimised complexes were injected into rat
brains and analysed by MRI and ﬂuorescent immunohistochemistry to
localise both vector distribution, indicated by Gd3+, and GFP reporter
gene expression. MRI distribution data was further validated by
LA-ICP-MS analysis of tissue sections.
2. Materials and methods
2.1. Cell lines
U87-MG human glioblastoma cells (ECACC, Porton Down, Wilts)
were maintained in Eagles MEM with Earle's balanced salt solution
containing 2 mM L-glutamine, 1% non-essential amino acids, 1 mM
sodium pyruvate, 10% FCS and antibiotic–antimycotic (Invitrogen,
Paisley, UK).
2.2. Lipids and peptides
1,2-Dioleoyl-3-(trimethylammonio)propane (DOTAP) and 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine
B sulfonyl) (ammonium salt) were obtained from Avanti Polar
lipids (Alabaster, AL, USA). Dioleoylphosphatidylethanolamine (DOPE)
and diethylenetriaminepentaacetic acid α,ω-bis(8-stearoylamido-3,6-
dioxaoctylamide) gadolinium salt (C62H116N7O14Gd; Mr 1340.87)
(Gd-DTPA-DSOA), [12], were obtained from Sigma Aldrich (Poole,
UK). Peptide P (K16GACLPHKSMPCG) and the control with a scrambled
targeting motif, peptide PS, (K16GACHPPMSKLCG) were synthesised by
Alta Biosciences (Birmingham, UK).
2.3. Liposome formulations and MRI analysis
Lipids were dissolved in chloroform at 10 mg/ml and mixed to
give formulations with a range of Gd-lipid content (0–20% of total
lipid) (Table 1) followed by production of a lipid ﬁlm by rotary evap-
oration at 40 °C. Lipids were rehydrated with sterile, distilled water
preheated to 40 °C to give a ﬁnal concentration of 1 mg/ml. Lipo-
somes were incubated at 4 °C overnight followed by sonication in a
water bath. MR imaging of liposome MW6 (Table 1) was performed
on a 9.4 T VNMRS horizontal bore (Agilent, Palo Alto, USA) using a
59/33 quadrature volume coil (Rapid, Würzburg, Germany), with
the dilution series placed into a Perspex holder within the RF coil.
The longitudinal relaxivity r1 was determined from a linear ﬁt of
1/T1 as a function of Gd3+ concentration.
2.4. Nanocomplex formation, biophysical analysis and MRI
Complexes were prepared by mixing components in the order
lipid:peptide:DNA (L:P:D) in the weight ratios of 1:4:1 (unless other-
wise stated) which corresponds to a free nitrogen to phosphate (N/P)
ratio of approximately +5. Formulations were prepared in OptiMEM
for cell culture, or in water for MRI and biophysical analysis, as de-
scribed previously [13]. The average diameter and zeta potential ofTable 1
Liposome formulations prepared (weight ratios).
DOTAP DOPE Gd lipid % Gd lipid
DOTAP/DOPE 1 1 0 0
MW5 0.8 1 0.2 10
MW6 0.7 1 0.3 15
MW7 0.6 1 0.4 20the nanocomplexes were determined using a Nano S Zetasizer
(Malvern Instruments, Malvern, UK) at a temperature of 25 °C, vis-
cosity of 0.89 cP and a refractive index of 1.33. The z-average value
was determined from ten size measurements on three occasions.
From this analysis the polydispersity index (PI) was obtained to de-
termine sample homogeneity with a value of >0.3 indicating a het-
erogeneous population. The zeta potentials of nanocomplexes were
determined from their electrophoretic mobilities in an electric ﬁeld
in the Nano S Zetasizer.
LD and LPD complexes for MRI analysis were prepared in water to a
total volume of 125 μl as follows: LD: 20 μg lipid in 87.5 μl water added
to 20 μg DNA in 37.5 μl water, LPD (lipid, peptide and DNA): 20 μg lipid
in 37.5 μl water, 80 μg peptide in 50 μl followed by 20 μg DNA in
37.5 μl. Complexes were mixed by pipetting up and down after the ad-
dition of the DNA and allowed to stand at room temperature for 30 min
before scanning.
2.5. Transfections and gene expression analysis
Cells were plated (10,000 per well) in 24-well plates then the
transfection complex formulated in OptiMEM was added in 200 μl
per well containing 250 ng of the luciferase-expressing plasmid
pCI-Luc. Plates were incubated for 4 h at 37 °C then replaced with
complete medium and incubated for a further 24 h at 37 °C before
preparing cell lysates and measuring luciferase gene expression by
luminometry by the kit instructions (Promega, Southampton, UK).
Luminescence as relative light units (RLU) was measured on an Opti-
ma Fluostar microplate reader (BMG Labtech, Aylesbury, UK) then the
protein concentration was measured using a Bio-Rad protein assay
(Hemel Hempstead, UK) and RLU values standardised to protein
values (RLU/mg). Cell viability assays were performed with the
CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega,
Southampton, UK).
2.6. Transfections for MRI analysis
U87-MG glioblastoma cells were plated at 0.5×106 cells per well
in 6-well plates then transfected as above but with complexes
containing 1 μg pCI-Luc plasmid in 1.5 ml OptiMEM. For image anal-
ysis by MRI, cells were trypsinised then pelleted and ﬁxed for
20 min in ice-cold, 1% paraformaldehyde-phosphate buffered saline
(PBS), before pelleting again and resuspending the pellet in 270 μl
PBS in a polypropylene tube and repelleting.
2.7. Magnetic resonance imaging of nanocomplexes and transfected cells
LPD nanocomplexes (MW6:P:pEGFP)were prepared inwater as de-
scribed above. MRI measurements were performed at room tempera-
ture on a 9.4 T VNMRS horizontal bore scanner (Varian Inc. Palo Alto,
CA) with a shielded gradient system (400 mT/m); 59/33 Rapid quadra-
ture volume coil. A T1 weighted spin echo sequence was acquired for
qualitative evaluation (matrix 384×192; ﬁeld of view 80×40 mm;
TR=500 ms; TE=19.4 ms; NSA=2; slc=0.5 mm). For quantitative
maps either an inversion recovery prepped spin echo sequence was ac-
quired (matrix 256×92; FOV 8×40 mm; TR=16,500 ms; TE=
16.9 ms; NSA=1; TI=100, 300, 500, 700, 900 and 16,000 ms) or a sat-
uration recovery (512×256 matrix, slc=0.5 mm, NSA=4, FOV
60×30 mm, TE=10.9 ms at TR=250–5000 ms). T1 maps were calcu-
lated on a pixel wise basis. The mean (±standard deviation) T1 relaxa-
tion time of individual cell pellets was obtained bymanually contouring
a region of interest around each pellet.
2.8. Confocal ﬂuorescence microscopy
1.5×105 U87-MG cells were seeded on 35 mm FluoroDishes
(World Precision Instruments Inc., FL, USA) in complete medium.
Table 2
Particle sizing and surface charge of nanoparticles in water.
Sample Particle size (nm) PDI Zeta PD (+mV)
Liposomes (L)
DOTAP/DOPE 68.0±1.0 0.21 27.4±4.3
MW5 63.5±0.6 0.23 49.2±0.8
MW6 69.7±0.5 0.23 27.6±1.8
MW7 58.5±0.4 0.21 24.6±2.6
Lipid/peptide/DNA (LPD)
DOTAP/DOPE 58.2±0.7 0.13 36.0±0.7
MW5 59.3±0.5 0.08 73.9±2.1
MW6 61±0.5 0.11 44.1±3.5
MW7 71.6±0.7 0.24 20.2±1.8
L = sonicated cationic liposome all formulated in a 1:1 ratio with DOPE.
LPD = Lipid+peptide+plasmid DNA nanocomplex (1:4:1 weight ratio).
PDI = polydispersity index.
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mulated as described previously with: pCI-Luc DNA labelled with Cy5 as
per manufacturer's protocol (Kreatech, Amsterdam, Netherlands), pep-
tide P and MW6:DOPE-rhodamine (99:1 wt/wt) at a 1:4:1 weight
ratio. Transfections were performed by adding complexes to wells
(0.5 μg pCILuc per well). After 1, 2, 4 and 6 h of incubation, the cells
were washed with PBS and ﬁxed in 4% formaldehyde, permeabilised
with 0.2% Triton, blocked with 1% BSA and stained for 20 min with
AlexaFluor 488 phalloidin (1:50, or 4U/ml, Invitrogen, Paisley, UK) and
DAPI (0.1 μg/ml, Sigma-Aldrich). The wells were washed and sealed in
mounting media (Invitrogen, Paisley, UK) before visualising on a Carl
Zeiss LSM710 laser scanning microscope system (Jena, Germany).
2.9. In vivo infusions
RTN vector formulations were prepared for in vivo use in 5% dex-
trose at a pEGFP DNA concentration of 0.32 mg/ml, and with MW6/
DOPE and peptide P at a weight ratio of 1:4:1 (L:P:D). All procedures
were carried out in accordance with the UK Home Ofﬁce regulations.
Male Wistar rats weighing 250 g (B&K Universal, Hull, UK) once
anaesthetised were placed in a stereotactic frame (Stoelting Co,
Wood Dale, Illinois, USA). Burr holes were used to allow cannula im-
plantation to corpus callosum or striatum using the following coordi-
nates: corpus callosum: 1.5 mm anterior and 2.5 mm lateral to the
bregma and 2.5 mm ventral; striatum: 0.75 mm anterior and
3.5 mm lateral to the bregma and 4.5 mm ventral. 4 l of MW6:P:
pEFGP nanocomplex formulation was infused using a 220 μm outer
diameter fused silica cannula connected to a 10 μl Hamilton syringe
at a rate of 0.5 μl/min at each site using an infusion pump (World Pre-
cision Instruments, Inc., Sarasota, Florida, USA). This corresponded to
a dose of 1.3 μg each of the DNA and MW6 lipid (containing 15%
Gd-3+ lipid by weight), and 5.2 μg of the peptide. Following infusion,
the cannula was left in situ for 5 min and withdrawn at a rate of
1 mm/min. Animals were killed 48 h after treatment by transcardial
perfusion ﬁxation using 4% paraformaldehyde (pH 7.4) under termi-
nal anaesthesia.
2.10. MRI and tissue processing of infused brains
Fixed rat brains were imaged using a T1-weighted spin echo se-
quence (TR=150 ms, TE=7 ms, 170 μm resolution, slc=0.5 mm)
and a T2*-weighted spoiled gradient echo sequence (TR=300 ms,
TE=5.5 ms, FA=60, 85 μm resolution, slc=0.5 mm). Brain section-
ing, and immunoﬂuorescence staining for microglial cells with mouse
anti-ED1 (1:100; Serotec, UK) were performed as described previous-
ly [14]. All microscopic images were obtained using a Leica DM5500
microscope and digital camera (MBF, Germany). Haematoxylin and
eosin staining was performed on sections to examine tissue morphol-
ogy after nanocomplex infusions.
2.11. Analysis of histological sections by laser ablation-inductively
coupled plasma mass spectrometry (LA-ICP‐MS)
The laser ablation system (UP-266 Macro LA system, Nd:YAG λ
266 nm, New Wave Research, Cambridgeshire, UK) was conﬁgured
to perform multiple parallel line rastering to generate elemental
(2D) distribution maps. A laser beam diameter of 155 μmwas utilised
for interrogation of sections. Laser energy was in the range of 1.4 mJ
at a frequency of 10 Hz, and the scanning speed was set to 55 μm/s.
The interrogated area was in the region of 140 mm2. The line rasters
were separated by 310 μm, to prevent contamination of adjacent tis-
sue with previous line raster runs. Complete analysis runtime was
178 min. Elemental maps were produced using the Graphis software
package (Kylebank Software Ltd., Ayr, UK). The isotopes 157Gd and
57Fe were monitored in a time-resolved mode using an Agilent 4500ICP‐MS and were selected on the basis of high-percentage abundance
and minimal interferences.
3. Results
3.1. Biophysical analysis of liposomes and nanocomplexes
Liposomes (L) were formulated with the cationic lipid DOTAP and
DOTAP+Gd-DTPA-DSOA (Gd-lipid), at a combined molar ratio relative
to DOPE of 1:1 (Table 1). Lipoplexeswith pCILuc plasmidDNA at aweight
ratio of 1:1 (L:D), and nanocomplexes comprising liposome, peptide and
pCILuc plasmid at a weight ratio of 1:4:1 (L:P:D) were formulated
(Table 2) in sterile, deionised water. MW6 liposomes (69.7 nm) were
similar in size to DOTAP/DOPE liposomes (68.0 nm) while MW5 lipo-
somes were slightly larger (63.5 nm) (pb0.05) and MW7 liposomes
(58.5 nm) were slightly smaller (pb0.05) than DOTAP/DOPE liposomes.
Nanocomplexes comprising liposomes MW5 (59.3 nm) and MW6
(61.0 nm) formulated with peptide K16GACLPHKSMPCG and plasmid
pCI-Luc were similar in size to nanocomplexes containing DOTAP/DOPE
(58.2 nm)while nanocomplexeswithMW7(71.6 nm)were signiﬁcantly
larger (pb0.05). Size analysis of all four nanocomplexes suggested a
single major peak with most particles in each group falling in a size
distribution ranging from 30 nm to 100 nm. All polydispersity values
were b0.3 indicating sufﬁcient sample homogeneity for reliability of the
measurements.
Based on a mixing ratio of 1:4:1 (L:P:D) and a molecular weight of
3.7×106 for pCILuc and 1340.87 for the Gd-lipid, we calculate the num-
ber of Gd centres per DNAmolecule to be 276 forMW5nanocomplexes,
414 for MW6 nanocomplexes and 552 for MW7 nanocomplexes. With
an estimated 1–5 DNA molecules per nanocomplex based on approxi-
mate volume calculations, the maximal numbers of Gd centres per
nanocomplex are 1380, 2070 and 2760 for MW5, MW6 and MW7
nanocomplexes respectively.
3.2. Transfection efﬁciency and cytotoxicity of Gd-containing nanocomplexes
LPD formulations were prepared comprising DOTAP/DOPE and ei-
ther peptide P, or control PS, at a series of weight ratios, varying pep-
tide with constant lipid weight ratio at 1:1 (L:D) (Fig. 1A) then
varying lipid with constant peptide (4:1, P:D) (Fig. 1B) and compared
for transfection efﬁciency in U87-MG cells. The optimal lipid ratio was
1:1 (L:D) by weight while the optimal peptide DNA weight ratio was
4:1 w/w. The peptide ratio 4:1 w/w P:D was critical for achieving
receptor-mediated transfection. At that ratio the transfection efﬁcien-
cy of peptide P targeted formulations was more than twice that of
untargeted, peptide Ps-mediated transfections (Fig. 1A). The transfec-
tion efﬁciency of formulations with a lipid:DNA ratio of 0.5:1 or
0.25:1 L:D w/w was signiﬁcantly lower than the transfection efﬁcien-
cy at 1:1 although increasing to 2:1 had no signiﬁcant effect (Fig. 1B).
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Fig. 2. Transfection efﬁciency of Gd-lipids and cytotoxicity of nanocomplexes. U87-MG
cells were transfected with formulations of peptide P and liposomes DOTAP/DOPE,
MW5, MW6 or MW7 then analysed by MRI. (A) Nanocomplexes with lipids DOTAP/
DOPE, MW5 or MW6 displayed similar levels of luciferase activity (RLU per mg)
while MW7 formulations were far less active (pb0.05). (B) A MTT toxicity assay was
performed following transfection and cell viability expressed as a percentage of the ab-
sorbance at 490 nm obtained from untransfected cells. DOTAP formulations were sig-
niﬁcantly more toxic than those with MW6 (pb0.05).
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glioblastoma cells were transfectedwith formulations containing either targeting peptide
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plasmid pCI-Luc. Luciferase expression (RLU/mg) was monitored at 48 h post transfec-
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343M.J. Writer et al. / Journal of Controlled Release 162 (2012) 340–348
G
E
N
E
D
E
L
IV
E
R
YFormulations of LD (no peptide) showed very low levels of transfec-
tion (not shown), indicating the functional importance of the peptide
component in the LPD mixture.
The transfection efﬁciency of LPD nanocomplex formulations
containingMW5orMW6was similar to that of homologous formulations
containing DOTAP while MW7 formulations were approximately 15-fold
less efﬁcient than DOTAP/DOPE LPD formulations (Fig. 2A). Viabilities of
cells exposed to LPD nanocomplexes containing DOTAP/DOPE were re-
duced to about 50% while those containing increasing amounts of
Gd-DTPA-DSOA displayed a trend for reduced toxicity (Fig. 2B), although
this is more likely a consequence of lower cationic DOTAP content
(Table 1). Cells transfected with MW6 and MW7 formulations showed
no signiﬁcant loss of viability relative to untransfected cells (p>0.05).
LD and LPD complexes containing liposomesMW5, MW6 andMW7
were compared in T1 measurements of complexes (Fig. 3A). The LPD
formulation suspensions displayed longer relaxation times compared
to homologous LD complexes, suggesting more limited accessibility of
the Gd3+ moiety to water [15] (Fig. 3A). MR images of pelleted cells
that had been incubated with MW5, MW6 and MW7 Gd3+‐labelled
nanocomplexes for 4 h at 37 °C showed obvious contrast enhancement
between cells and medium when compared with the untransfected
control cells (Fig. 3B). The relaxation times for the pellets from MW5,
MW6andMW7 transfected cellswere signiﬁcantly lower in LPD formu-
lations compared to LD complexes (Fig. 3C). Relaxation times did not
vary signiﬁcantly between LD formulations containing MW5, MW6 or
MW7 whereas LPD formulations showed a signiﬁcant shortening of T1
(pb0.05) from MW5 to MW6 (Fig. 3C). The increase in Gd3+ content
from MW6 (15% total lipid) to MW7 (20% total lipid) did not signiﬁ-
cantly increase contrast enhancement further. TheMW6 lipid appearedto offer the highest Gd3+ content whilst retaining transfection efﬁcien-
cy and sowas selected for ongoingMRI studies in cells and in vivo. MW6
had an r1 value of 2.8±0.02 mM−1 s−1.
To assess the potential for MRI detection of cells in the brain
transfected by Gd3+‐containing nanocomplexes, U87-MG cells
transfected with MW6-containing LPD formulations were injected
into one side of ﬁxed rat brain while a Gd3+‐free control LPD formu-
lation was injected on the other side and imaged. The Gd3+ treated
cells were highly conspicuous against the surrounding brain tissue
compared to the Gd-free control cells (Fig. 3D).3.3. Kinetics of MRI contrast enhancement
LPD nanocomplexes comprising peptide P with MW6 or DOTAP/
DOPE were prepared and incubated with U87-MG cells then analysed
by MRI at a series of time points from 30 min up to 24 h (Fig. 4). The
shortest T1 relaxation values were achieved after 4 h of incubation
and remained stable at least up to 8 h followed by a gradual increase
in relaxation time at 24 h. This time course suggested that theMRI con-
trast effect was enhanced by cellular uptake of nanocomplexes.3.4. Internalisation of nanocomplexes
To investigate the time-course of LPD transfections in cells in terms
of nanocomplex uptake and intracellular dissociation, U87-MG cells
were transfected with ﬂuorescently-labelled nanocomplexes containing
rhodamine-labelled lipid and Cy5-labelled plasmid and analysed by
confocal ﬂuorescence microscopy (Fig. 5).
Fig. 3. MRI analysis of formulations prepared with plasmid DNA, peptide P and lipo-
some (DOTAP/DOPE, MW5, MW6 or MW7), or lipid:DNA (LD; 1:1 weight ratio) with
no peptide. (A) Complexes of LPD or LD were formulated and analysed in microfuge
tubes by MRI. LPD nanocomplexes displayed reduced contrast compared to LD formu-
lations. Higher Gd3+ concentration in LD formulations led to increased contrast
(MW5➔MW7). (B) U87-MG cells were transfected with nanocomplex formulations
and displayed detectable contrast signals compared to untransfected cells (left-most
tube). (C) T1 values were calculated from MR images of cell pellets transfected with
LPD or LD formulations. (D) U87 cells transfected with MW6:P:pCILuc were injected
into ﬁxed rat brain and analysed by MRI, to assess the potential for in vivo detection.
Fig. 5. Confocal microscopy images showing cellular uptake of ﬂuorescently labelled LPD
nanocomplexes. U87-MG cells were transfected with LPD nanocomplexes containing
Cy5-labelled DNA (pink) and rhodamine-labelled liposome (red) and examined at serial
time points (1 h, 2 h, 4 h and 6 h). Arrows in 6d highlight Cy5-ﬂuorescence, while other
particles are rhodamine.
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served predominantly at the cell surface while rhodamine was barely
detectable. By 2 h, rhodamine ﬂuorescence was more readily detected,Time course of contrast effect
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Fig. 4. MRI time course in vitro. U87-MG cells were transfected with formulations of
MW6:P (Gd3+-labelled) or DOTAP/DOPE:P and analysed by MRI. Cells were incubated
with complexes for varying lengths of time at 37 °C. At the assay time point, unbound
complexes were washed from the cells, the cells harvested, ﬁxed and the cell pellet
analysed by MRI (8 h vs. 24 h pb0.0005).mostly co-localised with Cy5 as punctate staining in the cytoplasm,
suggesting endosomal location. Four to 6 h after transfection both
ﬂuorophores were more abundantly detected as punctate staining in
the cytoplasmic and perinuclear regions. While in many cases they
remained co-localised, the ﬂuorophores were detected apart more fre-
quently at this later time point (Fig. 5, 6 h). These observations support
the analysis of the MRI kinetics (Fig. 4) suggesting a process of
internalisation of intact particles followed by intracellular disassembly
and separation of the lipid from the DNA.
3.5. MRI, histology and LA-ICP-MS following in vivo infusion
The striatum and corpus callosum of the three rat brains were in-
fused by convection enhanced delivery (CED) with LPD nanocomplex
formulations containing DOTAP/DOPE or MW6 along with peptide P
and plasmid pEGFP at weight ratios of 1:4:1 (L:P:D) with DNA at a
concentration of 0.32 mg/ml. Animals were killed at 6 h, 24 h, and
48 h, and the brains were analysed by MRI then sectioned for histo-
logical and LA-ICP-MS analysis on adjacent tissue sections.
MRI analysis revealed a hyperintensity on T1-weighted spin-echo
images located in the vicinity of the cannula tip in the corpus callosum
due to the presence of Gd3+ complexes in the brain parenchyma
(Fig. 6A). The control images from rats receivingGd-free nanocomplexes
at 24 h and 48 h after injection did not show any areas of T1-weighted
hyperintensity (Fig. 6B). However at 6 h a strong MRI signal was ob-
served in the Gd3+-free control. Histologically, this animal presented
with signs of haemorrhage at the injection site (data not shown) and
iron within haemoglobin is a known potential confounding factor for
MRI analysis of Gd3+ distribution [16].
To further investigate the contrast effect observed by MRI, brain tis-
sue sections were analysed by LA-ICP-MS. In Gd3+-treated animals,
157Gd distribution maps from all three time points, 6 h, 24 h and 48 h,
detected Gd signals coinciding with the MRI contrast (Fig. 6A). The dis-
tribution of both MRI and LA-ICP-MS signals remained focal rather
than diffuse, even at 48 h, which is consistent with an intracellular
Fig. 7. EGFP transfection rat striatum. Rat brains were infused with DOTAP/DOPE:P:
pEGFP by CED then histological sections were analysed for localisation of GFP expres-
sion. The ﬁgure shows representative images of EGFP expression (a and d) detected
in the grey matter at 48 h in the presence of ED-1 positive cells (b and e).
Colocalisation of positive active microglia was detected within the region highlighted
by arrows towards co-localised cells (c and f).
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Fig. 6. MRI and LA-ICP-MS analysis following in vivo infusion. Rats were infused with
Gd3+-labelled nanocomplexes (MW6:P) on the left side only (48 h) or both left and
right sides (6 h and 24 h). Control rats were infused with Gd3+-free nanocomplexes
(DOTAP/DOPE:P) on both left and right sides of the brain. T1-weighted MR images
and LA-ICP-MS images of 157Gd and 57Fe distribution of individual rat brains at 6 h,
24 h and 48 h after injection treated with (B) MW6 LPD nanocomplex formulations
and (C) DOTAP/DOPE LPD control formulations. The Gd scale for all Gd images was
set to 500 counts and the Fe images to 30,000 counts.
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6 h and 48 h samples, LA-ICP-MS distribution of 57Fewas uniform, indi-
cating that the MRI signal was entirely associated with 157Gd (Fig. 6A).
However in the 24 h sample the MRI signal detected in the corpus
callosum and weakly in the striatumwas associated with the detection
of a discrete, high-intensity 57Fe region, probably arising from small
haemorrhages from the injections.
The LA-ICP-MS analysis of control samples treated with Gd3+-free
nanocomplexes showed residual background levels (b100 counts) of
157Gd suggesting some minor cross-contamination from previous
Gd-enriched samples (Fig. 6B). The 6 h control had a high signal on
MRI and histological evidence of haemorrhage; this was conﬁrmed by
a very intense 57Fe measurement in the ICP‐MS analysis. i.e., Fe was,
the likely source of the MRI signal. Iron was also detected (at very low
signal) in the 48 h control although there was no change apparent in
MRI contrast. It should be noted that the MRI and LA-ICP-MS images
at each time point are from individual animals and so it is not possible
to say from this experiment whether the differences in MRI and 157Gd
intensity are signiﬁcant.3.6. Fluorescence microscopy analysis for GFP and ED-1
GFP expression was detected by ﬂuorescence microscopy in brain
sections 48 h after the rats were infused with the MW6-containing
nanocomplexes (Fig. 7a, d). GFP expression was found in the immedi-
ate vicinity of the cannula track in the grey matter. Immunostaining
identiﬁed ED-1-positive microglial cells (Fig. 7b and e). The majority
of GFP-expressing cells co-localised with the ED-1 staining (Fig. 7cand f), indicating that the majority of transfected cells were
microglial.
4. Discussion
The aim of this work was to evaluate a receptor-targeted,
Gd3+-labelled nanoparticle formulation for the co-delivery of nucleic
acid therapeutics along with contrast agents for detection by MRI in
the brain. The potential for brain delivery with long-term expression
of transgenes has been reported for a non-viral, nanoparticle formula-
tion [1,2] and the principle of co-delivery of drug and contrast agents
for MRI with liposome formulations has been established in previous
studies where liposomes were labelled with Gd3+ for co-delivery of
drugs to monitor delivery to brain tumours in rats by CED [9] and
for real-time imaging of CED of viral gene therapy vectors using a
gadolinium contrast agent as a surrogate marker for location of the
virus [17]. In this study we aimed to combine these properties into
a single formulation for gene transfer and non-invasive detection of
vector localisation by MRI.
4.1. Gd3+-labelled LPD formulations — biophysical properties
The LPD nanocomplex formulation comprises an electrostatically
self-assembling mixture of cationic lipids, peptides and plasmid
DNA similar to formulations we have used previously for in vivo deliv-
ery to lung airways [18], for systemic targeted delivery to tumours
[13], and ex vivo to vein grafts [19]. The modularity of the lipid and
peptide components makes this system very useful for testing new
structural variations and delivery modalities. In this study we have
used a formulation of a peptide element comprising a cell-surface re-
ceptor targeting domain (LPHKSMP), and an oligolysine domain (K16)
for binding to anionic nucleic acids, separated by a short spacer
(\GA-) [20]. The cationic liposome comprised a formulation of cat-
ionic DOTAP, and the fusogenic lipid DOPE formulated into liposomes
in a 1:1 weight ratio. To enable detection by MRI, the DOTAP/DOPE li-
posome was substituted for one of a series of alternative
Gd3+-labelled liposomes, MW5, MW6 and MW7. In these liposomes
a Gd-lipid was substituted for DOTAP so that by weight the Gd-lipid
formed 10, 15 or 20% of the liposome formulation, while the DOPE
was retained at a constant 50% of total lipid (Table 1). The Gd-lipid
is incorporated into the liposome bilayer during the rehydration
step of liposome formulation.
The LPD nanocomplex formulations containing DOTAP/DOPE,
MW5 and MW6 along with the plasmid DNA and peptide P, were
all of similar size, and each signiﬁcantly smaller than their parent li-
posomes. LPD nanocomplexes made with MW7 were signiﬁcantly
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while their transfection efﬁciencieswere considerably lower suggesting
that the higher Gd3+ content destabilised the structure of the lipo-
somes and nanocomplexes. The MW6 lipid, containing 15% Gd-lipid of-
fered the optimal combination of highest Gd3+ content while retaining
transfection efﬁciency. The size range of DOTAP, MW5 and MW6 LPD
nanocomplexes measured by dynamic light scattering ranged from ap-
proximately 30–100 nm and all were highly cationic.
4.2. In vitro transfections with Gd3+-labelled LPD formulations
The Gd-free LPD formulation DOTAP/DOPE:P:pCILuc transfected
U87-MG cells in a receptor-enhanced manner at the optimal weight
ratio of L:P:D of 1:4:1. Transfection efﬁciency was 2-fold better than
that of a non-targeted LPD formulation, where binding is completely
non-speciﬁc due to the net cationic charge of the formulations (N/P
ratio of +5). The receptor targeting peptide LPHKSMP therefore en-
hanced transfection efﬁciency rather than providing absolute targeting
speciﬁcity. To achieve higher degrees of receptor speciﬁcity would like-
ly require anionic nanocomplexes to reduce non-speciﬁc cell binding.
The receptor-mediated enhancement of transfectionwas only observed
at one ratio of peptide:DNA (4:1) while higher and lower ratios of
peptide:DNA had a detrimental effect on transfection. This suggests
that the nanocomplexes containing peptide at the 4:1 ratio with DNA
have the optimal biophysical properties, receptor density and orienta-
tion for targeted transfection. The LPHKSMP targetingmotif was identi-
ﬁed previously by biopanning of a phage peptide library on epithelial
cells and it has close homology to the motif LHKSMP, occurring within
glycoprotein B of neurotrophic herpes simplex virus which is reported
to bind to cell-surface heparan sulphate, although the binding of pep-
tide P to this receptor moiety has not been conﬁrmed [20]. In epithelial
cell transfections nanocomplexes containing peptide P displayed a
twelve-fold enhancement over non-targeted control formulations
whereas in U87-MG cells the enhancement was only two fold
suggesting the possibility for improvement of targeted transfection
speciﬁcity and efﬁciency with alternative peptide ligand.
Nanocomplexes with 10% (MW5) or 15% Gd-lipid (MW6) incor-
porated in the liposome bilayer displayed similar transfection efﬁ-
ciencies to nanocomplexes containing Gd-free liposomes suggesting
that the lipid function in the transfection pathway such as endosomal
fusion [21], was unaffected by the altered lipid ratios or Gd lipid. The
transfection efﬁciency of nanocomplexes with 20% Gd-lipid (MW7)
however was signiﬁcantly compromised. The larger size and less pos-
itive zeta potential of the MW7-containing nanocomplexes may ex-
plain their lower transfection efﬁciency, lowering their potential for
cell binding and uptake.
The toxicity of nanocomplexes actually decreased with substitu-
tion of DOTAP for increasing amounts of the Gd-lipid due most likely
to reduced content of DOTAP, as cationic lipids are known to be cyto-
toxic. The optimal LPD formulation, offering highest Gd3+ content,
maximal transfection efﬁciency andminimal toxicity was therefore li-
posome MW6 with peptide P.
4.3. MRI analysis of in vitro transfections
Suspensions of MW6 LPD complexes exhibited lower contrast on
T1-weighted MR images than LD lipoplexes, (Fig. 3) which is most
likely due to the increased particle compaction imparted by the pep-
tide interacting with the DNA reducing accessibility of water to the
Gd-moiety in the liposome bilayer. Effects of cell interactions on
MRI conspicuity were then evaluated using U87-MG cells, a human
glioblastoma cell line as a potential model for the development of tu-
mour therapeutics. MRI analysis of U87-MG cells after transfection
with nanocomplexes containing MW6 produced a contrast enhance-
ment between cells and medium and reduced T1 relaxation times
while LD complexes did not show this effect. A kinetic analysis of T1relaxation in U87-MG cells transfected with the MW6 nanocomplex
formulation revealed that after 2 h, T1 had decreased and was
shortest at 4 h which was maintained up to 24 h when T1 increased.
We hypothesised that the observed enhancement of MRI conspicuity
over the ﬁrst 4 h of transfection with LPD nanocomplexes reﬂected
their progressive binding, internalisation, endosomal release and sub-
sequent disassembly within the cell, enhancing Gd3+ accessibility to
water. By 24 h, Gd3+ content may be becoming diluted by cell divi-
sion increasing the relaxation times.
We propose that the liposomal components of the LPD nanocomplex
contributes to enhanced endosomal escape via lipid bilayer fusion pro-
cesses, as suggested previously [22]. This hypothesis was tested for the
P:MW6 formulation by assessing cellular uptake and dissociation of
nanocomplexes containing Cy5 plasmid DNA and rhodamine‐labelled
lipids by confocalﬂuorescencemicroscopy. In theﬁrst hour after transfec-
tion cell binding andentry occurred,while by2 h, particlesweremore ap-
parent in the cytoplasmic region. It was striking in the ﬁrst hour that
while Cy5 was readily detected the rhodamine label was not detectable.
This could be due to nanocomplexes remaining tightly compacted and
so quenching the rhodamine. By 2–4 h the endocytosed particles
appeared to be undergoing disassembly as rhodamine ﬂuorescence be-
came more apparent, although the two ﬂuorophores remained
colocalised. However, by 6 h the ﬂuorophores were more frequently
detected separately, suggesting that the DNA and lipid had dissociated.
Thus the confocal analysis suggests a process and kinetics of Gd-labelled
LPDnanocomplex trafﬁcking compatiblewith the kinetics ofMRI contrast
enhancement, supporting the proposal above that MRI conspicuity is en-
hanced by cellular internalisation and complex disassembly. Other
lipoplex andpolyplex formulations showsimilar kinetics of cell trafﬁcking
and complex dissociation [23].
In contrast, reports of most other liposome-based Gd3+-formulations
showed that they are quenched upon intracellular localisation,whichwas
explained as a consequence of endosomal retentionwhere access of Gd3+
in the liposome to water is more restricted [8,24]. In those studies, lipo-
somes rather than lipoplex with plasmid DNA were used which may
have different properties and interactions with cells and less able to es-
cape the endosome than LPD formulations.
4.4. MRI analysis of in vivo transfections
We then investigated the in vivo potential of Gd3+-labelled LPD
nanocomplexes as contrast agents, performing a pilot study that involved
injecting MW6-transfected U87-MG cells into a rat brain stereotactically.
Transfected cells were readily detectable by MRI, indicating that cells
containing sufﬁcient amounts of the Gd3+-labelled nanocomplex can po-
tentially be detected byMRI in vivo. Based on that ﬁnding, MW6:P:pEGFP
formulations were then injected into the rat striatum or corpus callosum
by CED. Brains analysed by MRI revealed a weak signal at 6 h but strong
T1-weighted signals at 24 h and 48 h after delivery. Similar MRI contrast
intensity kinetics were observed in vivo in a tumourmodel using lipoplex
containing Gd3+ chelates [25].
These experiments used normal healthy rats to evaluate the con-
cepts but future studies could use orthotopic brain tumour models,
correlating tumour targeted gene delivery with MRI analysis. Gado-
linium contrast agents based on the macrocyclic gadolinium chelator,
DOTA could be used in future studies in the same LPD format which
would be far more kinetically stable than acyclic gadolinium chela-
tors, making them more persistent for imaging purposes and less
toxic in vivo [26]. However, the DTPA reagent used here was adequate
for proof of concept studies.
4.5. LA-ICP-MS analysis for MRI validation
Unexpectedly, a strong MRI signal was detected in the 6 h control
brain, although it had been treated with a Gd-free LPD formulation.
Histological analysis of sections of this brain revealed a small degree
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insertion site, suggesting the possibility of a contrast signal arising
from iron from blood products released in the haemorrhage site. To
address this inconsistency in the MRI data, brain tissue sections
from all animals, particularly regions associated with contrast effects,
were analysed by LA-ICP-MS, a powerful technique for imaging of the
distribution and relative concentration of speciﬁc metal ions in tissue
sections. This technique provides a higher degree of resolution and
sensitivity than MRI and an independent means of validating the
MRI data [27]. Analysis revealed that all hyperintense MRI signals in
the Gd3+-nanocomplex treated animals at 6 h, and 48 h were associ-
ated solely with 157Gd atoms, while in the 24 h animal the signal on
the right side of the brain was mainly from 157Gd but was also associ-
ated with paramagnetic iron (57Fe). In the 6 h control animal, which
received no Gd3+, there was a strong MRI signal but LA-ICP-MS anal-
ysis revealed that this signal was associated solely with 57Fe arising
from haemorrhage at the site of injection. This study therefore pro-
vides a compelling example of the capacity of LA-ICP-MS to unambig-
uously differentiate different metal ions as sources of MRI contrast
effects, such as iron-associated haemorrhage, allowing sensitive vali-
dation of MR images [16].
4.6. Histological analysis of in vivo transfection
Although the targeted Gd-LPD nanocomplex formulation was
optimised for transfection of U87-MG glioblastoma cells, in vivo it
demonstrated efﬁcient GFP transfection in rat brain of ED-1-positive
microglial cells. This observation itself opens up the possibility of de-
veloping gene therapy treatment for gliomas since glioma tissue con-
sists of up to 30% of microglial cells which contribute to tumour cell
invasion [28] making them potential targets for gene-based therapeu-
tics. Future studies using orthotopic models of brain tumours will ex-
plore this possibility further as well as targeted transfection of the
tumour itself. The fact that no transfection was observed in neurons
stained with NeuN antibodies (data not shown) suggests the possibil-
ity of delivering therapeutics speciﬁcally to tumour-associated cells.
Other diseases that may be treated by microglial-targeted gene ther-
apies include lysosomal storage diseases, such as metachromatic leu-
kodystrophy (MLD) caused by deﬁciency of the enzyme for
arylsulfatase A [29].
4.7. Implications for future studies
Future studies will aim to improve the in vivo performance of
the LPD formulation in terms of its transfection and targeting efﬁcien-
cy, and to increase the extent of dispersal which will require modulat-
ing the biophysical properties of the nanocomplexes. For example,
while the LPD size distribution and cationic charge is typical for
self-assembling electrostatic complexes it is not optimal for maximal
distribution in the brain by CED where it has been shown that anionic
or neutral particles distributed much better than cationic particles [6].
A similar problem of poor distribution was observed with a cationic
HIV TAT peptide modiﬁed DNA nanolipoparticle administered to rat
brain by CED [7]. Further, a size of 80 nm or less gave much better dis-
tribution than particles of 200 nm. Thus, while the majority of LPD
nanoparticles produced (30–100 nm) are within the proposed opti-
mal size range their cationic charge is probably restricting the extent
of their distribution in brain by CED and future studies will aim to
produce neutral or anionic LPD nanocomplexes with a narrower size
distribution range.
Combining contrast agents with nanoparticle gene therapy formu-
lations could offer new modalities for the non-invasive, real time
monitoring of therapeutic gene delivery formulations, for example
changes in their localisation over time in relation to targets sites, per-
sistence. MRI is also useful for evaluating the outcome of a CED proce-
dure, which can be highly dependent on cannula localisation andpossible reﬂux along the needle track. Such formulations could lead
to the development of new therapeutics for diseases of the brain in-
cluding cancers and neurodegenerative diseases.
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